Skip to content
Screener

Insight Molecular Diagnostics Inc. IMDX Q3 2025 earnings

Reported November 10, 2025 · After market close

Revenue$260.0KMiss by $25.0K
EPS-$0.34Miss by $0.10
Revenue estimate$285.0K
EPS estimate-$0.24

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$215.1K
EPS estimate-$0.23

Financials

Q3 2025

Income statement

See full
Revenue$260.0K+126%
Gross profit$139.0K+93.1%
Operating income-$11.0M+18.3%
Net income-$10.9M+19.6%
EPS (diluted)-$0.34+65.3%

Balance sheet

See full
Cash & equivalents$18.7M+456%
Total debt$2.9M-23.4%
Total equity-$9.2M-195%
Total assets$43.9M-37.4%

Cash flow

See full
Operating cash flow-$4.6M+16.3%
CapEx$1.1M+1,107%
Free cash flow-$5.7M-1.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$95.02M—
Enterprise value$79.27M—
P/S21.6×—

Profitability

See full
Gross margin55%—
Operating margin-1,392.9%-607pp
Net margin-1,380.7%-602pp
FCF margin-543.2%-243pp

Returns & leverage

See full
Current ratio2.8×+2.3×

Segments

By geography

See full
Asia Pacific-—
Europe-—

FAQ

When did Insight Molecular Diagnostics Inc. report Q3 2025 earnings?
Insight Molecular Diagnostics Inc. (IMDX) reported Q3 2025 earnings on November 10, 2025 after market close.
What were Insight Molecular Diagnostics Inc.'s Q3 2025 revenue and EPS?
Insight Molecular Diagnostics Inc. reported revenue of $260.0K and eps of $-0.34 for Q3 2025.
Did Insight Molecular Diagnostics Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $285.0K by $25.0K. EPS missed the consensus estimate of $-0.24 by $0.10.
How did Insight Molecular Diagnostics Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 126.1% from $115.0K a year earlier and eps grew 65.3% from $-0.98.
Where can I find Insight Molecular Diagnostics Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001493152-25-021513) and the 10-Q periodic report (0001193125-25-274266) directly on SEC EDGAR. The filing index links above go to sec.gov.